Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Mar 6;82(7):1305–1311. doi: 10.1054/bjoc.1999.1096

A unique cytosolic activity related but distinct from NQO1 catalyses metabolic activation of mitomycin C

P Joseph 1, A K Jaiswal 1
PMCID: PMC2374494  PMID: 10755406

Abstract

Mitomycin C (MMC) is a prototype bioreductive drug employed to treat a variety of cancers including head and neck cancer. Among the various enzymes, dicoumarol inhibitable cytosolic NAD(P)H:quinone oxidoreductase1 (NQO1) was shown to catalyse bioreductive activation of MMC leading to cross-linking of the DNA and cytotoxicity. However, the role of NQO1 in metabolic activation of MMC has been disputed. In this report, we present cellular and animal models to demonstrate that NQO1 may play only a minor role in metabolic activation of MMC. We further demonstrate that bioreductive activation of MMC is catalysed by a unique cytosolic activity which is related but distinct from NQO1. Chinese hamster ovary (CHO) cells were developed that permanently express higher levels of cDNA-derived NQO1. These cells showed significantly increased protection against menadione toxicity. However, they failed to demonstrate higher cytotoxicity due to exposure to MMC under oxygen (normal air) or hypoxia, as compared to the wild-type control CHO cells. Disruption of the NQO1 gene by homologous recombination generated NQO1–/– mice that do not express the NQO1 gene resulting in the loss of NQO1 protein and activity. The cytosolic fractions from liver and colon tissues of NQO1–/– mice showed similar amounts of DNA cross-linking upon exposure to MMC, as observed in NQO1+/+ mice. The unique cytosolic activity that activated MMC in cytosolic fractions of liver and colon tissues of NQO1–/– mice was designated as cytosolic MMC reductase. This activity, like NQO1, was inhibited by dicoumarol and immunologically related to NQO1. © 2000 Cancer Research Campaign

Keywords: mitomycin C, a unique cytosolic activity, NAD(P)H:quinone oxidoreductase1 (NQO1), mechanism of activation, DNA cross-linking

Full Text

The Full Text of this article is available as a PDF (155.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Dulhanty A. M., Whitmore G. F. Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res. 1991 Apr 1;51(7):1860–1865. [PubMed] [Google Scholar]
  2. IYER V. N., SZYBALSKI W. MITOMYCINS AND PORFIROMYCIN: CHEMICAL MECHANISM OF ACTIVATION AND CROSS-LINKING OF DNA. Science. 1964 Jul 3;145(3627):55–58. doi: 10.1126/science.145.3627.55. [DOI] [PubMed] [Google Scholar]
  3. Jaiswal A. K., Burnett P., Adesnik M., McBride O. W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry. 1990 Feb 20;29(7):1899–1906. doi: 10.1021/bi00459a034. [DOI] [PubMed] [Google Scholar]
  4. Jaiswal A. K., McBride O. W., Adesnik M., Nebert D. W. Human dioxin-inducible cytosolic NAD(P)H:menadione oxidoreductase. cDNA sequence and localization of gene to chromosome 16. J Biol Chem. 1988 Sep 25;263(27):13572–13578. [PubMed] [Google Scholar]
  5. Joseph P., Xu Y., Jaiswal A. K. Non-enzymatic and enzymatic activation of mitomycin C: identification of a unique cytosolic activity. Int J Cancer. 1996 Jan 17;65(2):263–271. doi: 10.1002/(SICI)1097-0215(19960117)65:2<263::AID-IJC22>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  6. Kaufman R. J., Davies M. V., Wasley L. C., Michnick D. Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus. Nucleic Acids Res. 1991 Aug 25;19(16):4485–4490. doi: 10.1093/nar/19.16.4485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kennedy K. A., Teicher B. A., Rockwell S., Sartorelli A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem Pharmacol. 1980 Jan 1;29(1):1–8. doi: 10.1016/0006-2952(80)90235-x. [DOI] [PubMed] [Google Scholar]
  8. Knox R. J., Boland M. P., Friedlos F., Coles B., Southan C., Roberts J. J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol. 1988 Dec 15;37(24):4671–4677. doi: 10.1016/0006-2952(88)90336-x. [DOI] [PubMed] [Google Scholar]
  9. Marshall R. S., Paterson M. C., Rauth A. M. DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis. 1991 Jul;12(7):1175–1180. doi: 10.1093/carcin/12.7.1175. [DOI] [PubMed] [Google Scholar]
  10. Plumb J. A., Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer. 1994 Jan 2;56(1):134–139. doi: 10.1002/ijc.2910560124. [DOI] [PubMed] [Google Scholar]
  11. Powis G., Gasdaska P. Y., Gallegos A., Sherrill K., Goodman D. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res. 1995 Jul-Aug;15(4):1141–1145. [PubMed] [Google Scholar]
  12. Radjendirane V., Joseph P., Lee Y. H., Kimura S., Klein-Szanto A. J., Gonzalez F. J., Jaiswal A. K. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem. 1998 Mar 27;273(13):7382–7389. doi: 10.1074/jbc.273.13.7382. [DOI] [PubMed] [Google Scholar]
  13. Rauth A. M., Goldberg Z., Misra V. DT-diaphorase: possible roles in cancer chemotherapy and carcinogenesis. Oncol Res. 1997;9(6-7):339–349. [PubMed] [Google Scholar]
  14. Riley R. J., Workman P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol. 1992 Apr 15;43(8):1657–1669. doi: 10.1016/0006-2952(92)90694-e. [DOI] [PubMed] [Google Scholar]
  15. Robertson N., Stratford I. J., Houlbrook S., Carmichael J., Adams G. E. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol. 1992 Aug 4;44(3):409–412. doi: 10.1016/0006-2952(92)90429-m. [DOI] [PubMed] [Google Scholar]
  16. Ross D., Beall H., Traver R. D., Siegel D., Phillips R. M., Gibson N. W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. Oncol Res. 1994;6(10-11):493–500. [PubMed] [Google Scholar]
  17. Sakai A., Miyata N., Takahashi A. Initiating activity of quinones in the two-stage transformation of BALB/3T3 cells. Carcinogenesis. 1995 Mar;16(3):477–481. doi: 10.1093/carcin/16.3.477. [DOI] [PubMed] [Google Scholar]
  18. Sartorelli A. C. Therapeutic attack of hypoxic cells of solid tumors: presidential address. Cancer Res. 1988 Feb 15;48(4):775–778. [PubMed] [Google Scholar]
  19. Shaw P. M., Reiss A., Adesnik M., Nebert D. W., Schembri J., Jaiswal A. K. The human dioxin-inducible NAD(P)H: quinone oxidoreductase cDNA-encoded protein expressed in COS-1 cells is identical to diaphorase 4. Eur J Biochem. 1991 Jan 1;195(1):171–176. doi: 10.1111/j.1432-1033.1991.tb15691.x. [DOI] [PubMed] [Google Scholar]
  20. Siegel D., Gibson N. W., Preusch P. C., Ross D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res. 1990 Nov 15;50(22):7293–7300. [PubMed] [Google Scholar]
  21. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  22. Stratford I. J., Stephens M. A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):973–976. doi: 10.1016/0360-3016(89)90898-5. [DOI] [PubMed] [Google Scholar]
  23. Talalay P., Fahey J. W., Holtzclaw W. D., Prestera T., Zhang Y. Chemoprotection against cancer by phase 2 enzyme induction. Toxicol Lett. 1995 Dec;82-83:173–179. doi: 10.1016/0378-4274(95)03553-2. [DOI] [PubMed] [Google Scholar]
  24. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res. 1994;6(10-11):461–475. [PubMed] [Google Scholar]
  25. Wu K., Knox R., Sun X. Z., Joseph P., Jaiswal A. K., Zhang D., Deng P. S., Chen S. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase. Arch Biochem Biophys. 1997 Nov 15;347(2):221–228. doi: 10.1006/abbi.1997.0344. [DOI] [PubMed] [Google Scholar]
  26. Zilfou J. T., Smith C. D. Differential interactions of cytochalasins with P-glycoprotein. Oncol Res. 1995;7(9):435–443. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES